Waxman S, Huang Y, Scher B M, Scher M
Rochelle Belfer Chemotherapy Foundation Laboratory, Department of Medicine, Mount Sinai Medical Center, New York, NY 10029.
Biomed Pharmacother. 1992;46(5-7):183-92. doi: 10.1016/0753-3322(92)90081-h.
We have previously shown that pretreatment of mouse erythroleukemia (MEL) cells with the fluorinated pyrimidines 5-fluorouracil (FUra) or 5-fluorodeoxyuridine (FUdR) followed by the differentiation inducer hexamethylene bisacetamide (HMBA) greatly enhanced the magnitude of their differentiation and caused extensive cell death. We have now extended these studies to address the mechanism that may be responsible for this enhancement and have also examined a human leukemic cell line (HL-60) for its sensitivity to this combination cytotoxic-differentiation therapy. We found that in HL-60 cells, pretreatment with FUdR, but not FUra, followed by 1.2% dimethylsulfoxide (DMSO) led to an 8 to 10-fold enhancement of cell death as compared to FUdR alone. When all-trans-retinoic acid (ATRA) was used instead of DMSO, the enhancement of differentiation and cytotoxicity was 5-fold. The percent of cells induced to differentiate was dependent on the concentration of both FUdR and ATRA. In HL-60 cells resistant to ATRA-induced differentiation, the combination of FUdR and ATRA did not result in enhanced cytotoxicity. Leucovorin (LV), a compound known to enhance the inhibitory effect of FUra or FUdR on DNA synthesis, increased the effectiveness of the cytotoxic-differentiation therapy, whereas thymidine inhibited its effectiveness. This suggests that inhibition of DNA metabolism may be an integral part of the differentiation-enhancing cytotoxic mechanism. To further explore inhibition of DNA synthesis, DNA was extracted under alkaline or neutral conditions from 3H-thymidine-labelled cells that were treated with FUra/LV and HMBA individually or in combination. The emergence of single and double-strand DNA breaks was monitored by agarose gel electrophoresis. In parallel to the enhancement of cytotoxicity, the combination treatment (FUra/LV followed by HMBA) also produced a 2.5-3-fold increase in the DNA breaks when compared to the same effect obtained by the agents applied individually. Thus, we propose that DNA degradation may be the mechanism responsible for the enhanced loss of cell viability. In summary, we report here an approach which is targeted to increasing the death rate of leukemic cells through the combined use of low doses of cytotoxic drugs and differentiation inducers.
我们之前已经表明,用氟代嘧啶5-氟尿嘧啶(FUra)或5-氟脱氧尿苷(FUdR)预处理小鼠红白血病(MEL)细胞,随后使用分化诱导剂六亚甲基双乙酰胺(HMBA),可极大地增强其分化程度并导致广泛的细胞死亡。我们现在扩展了这些研究,以探讨可能导致这种增强的机制,并且还检测了人白血病细胞系(HL-60)对这种联合细胞毒性-分化疗法的敏感性。我们发现,在HL-60细胞中,用FUdR而非FUra预处理,随后用1.2%二甲基亚砜(DMSO)处理,与单独使用FUdR相比,细胞死亡增加了8至10倍。当使用全反式维甲酸(ATRA)代替DMSO时,分化和细胞毒性的增强为5倍。诱导分化的细胞百分比取决于FUdR和ATRA的浓度。在对ATRA诱导的分化具有抗性的HL-60细胞中,FUdR和ATRA的组合并未导致细胞毒性增强。亚叶酸(LV)是一种已知可增强FUra或FUdR对DNA合成抑制作用的化合物,它增加了细胞毒性-分化疗法的有效性,而胸腺嘧啶则抑制其有效性。这表明抑制DNA代谢可能是增强分化的细胞毒性机制的一个组成部分。为了进一步探索对DNA合成的抑制作用,在碱性或中性条件下从用FUra/LV和HMBA单独或联合处理的3H-胸腺嘧啶标记的细胞中提取DNA。通过琼脂糖凝胶电泳监测单链和双链DNA断裂的出现。与细胞毒性的增强平行,联合处理(FUra/LV随后用HMBA)与单独使用这些试剂相比,DNA断裂也增加了2.5至3倍。因此,我们提出DNA降解可能是导致细胞活力增强丧失的机制。总之,我们在此报告一种通过联合使用低剂量细胞毒性药物和分化诱导剂来提高白血病细胞死亡率的方法。